Julia G. Butchko - Oct 5, 2023 Form 4 Insider Report for Immunovant, Inc. (IMVT)

Signature
/s/ Eva Renee Barnett, attorney-in-fact for Julia G. Butchko
Stock symbol
IMVT
Transactions as of
Oct 5, 2023
Transactions value $
-$62,885
Form type
4
Date filed
10/6/2023, 05:15 PM
Previous filing
Aug 25, 2023
Next filing
Nov 24, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IMVT Common Stock Sale -$10.5K -296 -0.07% $35.54 416K Oct 5, 2023 Direct F1, F2
transaction IMVT Common Stock Sale -$52.4K -1.44K -0.35% $36.39 415K Oct 5, 2023 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On March 19, 2021, the holder was granted 54,500 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on March 23, 2021, of which 3,406 of these RSUs vested on October 1, 2023. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs and do not represent a discretionary sale by the holder.
F2 The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $34.90 - $35.89 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4.
F3 The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $35.92 - $36.83 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4